<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Elderly patients constitute a subpopulation with special characteristics that differ from those of the general population and have been under-represented in clinical trials </plain></SENT>
<SENT sid="1" pm="."><plain>We, prospectively, analyzed the toxicity and efficacy of the original FOLFOX4-regimen in the treatment of elderly patients affected by metastatic (m) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-six consecutive patients aged 67-82 years (median age 72 years), 22 males and 14 females, with mCRC and <z:e sem="disease" ids="C1513041" disease_type="Disease or Syndrome" abbrv="">measurable disease</z:e>, were enrolled in the study </plain></SENT>
<SENT sid="3" pm="."><plain>The primary site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> was the liver (36.1% of patients) </plain></SENT>
<SENT sid="4" pm="."><plain>The median ECOG Performance Status (PS) was 1 </plain></SENT>
<SENT sid="5" pm="."><plain>The main hematological and extra-hematological (grade 3 or 4) toxicities were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (38.9%) and neurological (13.9%), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>A total of 36 patients, aged 67-82 years were included </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-two and 14 patients were male and female, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The median age was 72 years (range 67-82) </plain></SENT>
<SENT sid="9" pm="."><plain>The primary site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> was the liver (36.1% of patients) </plain></SENT>
<SENT sid="10" pm="."><plain>The median ECOG Performance Status (PS) was 1 </plain></SENT>
<SENT sid="11" pm="."><plain>The overall response rate (ORR) was 44.4% and similar to original study </plain></SENT>
<SENT sid="12" pm="."><plain>Median progression-free survival (PFS) was 7.5 months and median overall survival (OS) was 16 months </plain></SENT>
<SENT sid="13" pm="."><plain>The main hematological and extra-hematological (grade 3 or 4) toxicities were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (38.9%) and neurological (13.9%), respectively </plain></SENT>
<SENT sid="14" pm="."><plain>Tolerability, however, was manageable and no toxic <z:hpo ids='HP_0011420'>death</z:hpo> occurred </plain></SENT>
<SENT sid="15" pm="."><plain>FOLFOX4-regimen maintains its efficacy, and safety ratio in elderly patients with mCRC and good performance status </plain></SENT>
<SENT sid="16" pm="."><plain>It would be considered the treatment of choice in the treatment of this particular setting of patients </plain></SENT>
</text></document>